美国非酒精性脂肪性肝炎生物标记市场规模、份额和趋势分析报告：按类型、最终用途和细分市场预测，2024-2030 年

美国非酒精性脂肪性肝炎生物标记市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，美国非酒精性脂肪性肝炎生物标记市场规模将达到28.4亿美元，2024年至2030年复合年增长率为23.9%，预计将增长% 。

肥胖、2 型糖尿病和METABOLIC INC.症候群盛行率的增加导緻美国人口中非酒精性脂肪性肝炎 (NASH) 的发生率不断增加，从而推动了对生物标记的需求。根据美国国家医学图书馆的数据，肝硬化和慢性肝病 (CLD) 是全球健康危害，每年导致 110 万人死亡，使 CLD 成为全球第 11 大死因。

这个市场正在经历重大的技术创新，重点是开拓新的生物标记，以准确诊断和监测 NASH（一种由脂肪堆积引起的肝臟疾病）。这些生物标记对于早期发现 NASH 患者、监测疾病进展和评估治疗效果至关重要。公司和研究机构正在积极开发这些生物标记，以解决现有诊断工具的局限性，并提供有关疾病状态的更准确的资讯。

行动应用程式、穿戴式装置和人工智慧 (AI) 演算法等数位健康技术被用来开髮用于 NASH 诊断和监测的新型生物标记。广泛的临床资料集的使用和人工智慧应用的最新进展为提高诊断准确性创造了巨大的潜力。 2023 年6 月，Kinetix 集团的NASHNET 卓越网络将回顾生物标记物在非酒精性脂肪性肝病(NAFLD) 和NASH 的诊断和分期方面的当前状况和潜在的未来应用，我们已发布了一份探讨该问题的白皮书。

美国非酒精性脂肪性肝炎生物标记市场报告亮点

• 从类型来看，血清生物标记领域将在2023年以32.5%的销售份额占据市场主导地位。血清生物标记已成为医疗保健专业人员的重要工具，因为它们可以提供有关疾病进展和治疗效果的宝贵见解。
• 由于肥胖、久坐生活方式和METABOLIC INC.症候群的增加，预计肝纤维化生物标记在预测期内将以最快的速度增长。
• 2023年，最终用途领域製药和CRO产业主导市场。这一增长是由美国医疗保健支出和意识的增加所推动的，特别是对于慢性和复杂疾病。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国非酒精性脂肪性肝炎生物标记市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 相关/附随市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 美国非酒精性脂肪性肝炎生物标记市场分析工具
  • 产业分析-波特五力分析
  • PESTEL分析

第四章美国非酒精性脂肪性肝炎生物标记市场：类型估计和趋势分析

• 2023 年和 2030 年按类型分類的市场占有率
• 细分仪表板
• 美国非酒精性脂肪性肝炎生物标记市场展望（按类型）
• 2018-2030年市场规模、预测及趋势分析
• 血清生物标记
• 肝纤维化生物标记
• 细胞凋亡生物标誌物
• 氧化压力标誌物
• 其他的

第五章美国非酒精性脂肪性肝炎生物标记市场：最终用途估计与趋势分析

• 2023 年及 2030 年最终用途市场占有率
• 细分仪表板
• 美国非酒精性脂肪性肝炎生物标记市场前景（按最终用途）
• 2018-2030年市场规模、预测及趋势分析
• 製药/CRO产业
• 医院
• 诊断实验室
• 学术研究所

第六章美国非酒精性脂肪性肝炎生物标记市场：区域估计与趋势分析

• 2023 年及 2030 年区域市场占有率分析
• 美国非酒精性脂肪性肝炎生物标记市场：区域展望
• 2018-2030年市场规模及预测趋势分析：
  • 西
  • 中西部
  • 东北
  • 西南
  • 东南

第七章 竞争格局

• 主要市场参与企业的最新趋势和影响分析
• 公司/竞争对手分类
• 供应商情况
• 公司简介
  • GENFIT
  • Prometheus Laboratories
  • Siemens Medical Solutions USA, Inc.
  • Quest Diagnostics
  • AstraZeneca
  • Laboratory Corporation of America Holdings
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The U.S. non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 2.84 billion by 2030 and is anticipated to expand at a CAGR of 23.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of obesity, type 2 diabetes, and metabolic syndrome contribute to the growing incidence of non-alcoholic steatohepatitis (NASH) in the U.S. population, which is fueling the demand for biomarkers. According to the National Library of Medicine, Cirrhosis and chronic liver disease (CLD) are major worldwide health burdens leading to 1.1 million deaths yearly, and CLD ranks as the eleventh most common cause of death worldwide.

The market is experiencing significant innovation, primarily focused on developing novel biomarkers to accurately diagnose and monitor NASH, a liver disease caused by fat accumulation. These biomarkers are crucial for early detection, disease progression monitoring, and assessing treatment response in NASH patients. Companies and research institutions are actively developing these biomarkers to address the limitations of existing diagnostic tools and provide more accurate information about the disease status.

Digital health technologies such as mobile apps, wearable devices, and artificial intelligence (AI) algorithms are being used to develop novel biomarkers for NASH diagnosis and monitoring. The use of extensive clinical data sets and the latest advancements in AI applications have created a strong potential to increase diagnostic accuracy. In June 2023, the Kinetix Group's NASHNET network of excellence published a white paper that explored current perspectives and potential future applications of biomarkers for diagnosing and staging non-alcoholic fatty liver disease (NAFLD) and NASH.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

• Based on the type, the serum biomarkers segment dominated the market with a revenue share of 32.5% in 2023. The ability of serum biomarkers to provide valuable insights into disease progression and treatment response has made them indispensable tools for healthcare professionals
• The hepatic fibrosis biomarkers is expected to grow at the fastest rate during the forecast period due to the rising number of obesity, people following sedentary lifestyles, and metabolic syndromes
• The pharma & CRO industry in end-use segment dominated the market in 2023. This growth is attributable to the increasing healthcare expenditure and awareness in the U.S., particularly for chronic and complex diseases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End-use
  • 1.2.3. Region
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. End-use Outlook
  • 2.2.3. Region Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Non-alcoholic Steatohepatitis Biomarkers Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Serum biomarkers
    • 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. Hepatic fibrosis biomarkers
    • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. Apoptosis biomarkers
    • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.4. Oxidative stress biomarkers
    • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. U.S. Non-alcoholic Steatohepatitis Biomarkers Market: End-use Estimates & Trend Analysis

• 5.1. End-use Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market by End-use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Pharma & CRO industry
    • 5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.2. Hospitals
    • 5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.3. Diagnostic labs
    • 5.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.4. Academic Research Institutes
    • 5.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. U.S. Non-alcoholic Steatohepatitis Biomarkers Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. U.S. Non-alcoholic Steatohepatitis Biomarkers Market by Region Outlook
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3.1. West
    • 6.3.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.2. Midwest
    • 6.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.3. Northeast
    • 6.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.4. Southwest
    • 6.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.5. Southeast
    • 6.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company heat map analysis, 2023
• 7.4. Company Profiles
  • 7.4.1. GENFIT
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Prometheus Laboratories
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Siemens Medical Solutions USA, Inc.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Quest Diagnostics
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. AstraZeneca
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Laboratory Corporation of America Holdings
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Pfizer, Inc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Bristol-Myers Squibb Company
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. non-alcoholic steatohepatitis biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 3 U.S. non-alcoholic steatohepatitis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 4 U.S. non-alcoholic steatohepatitis biomarkers market, by region, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. non-alcoholic steatohepatitis biomarkers market: Market outlook
• Fig. 9 U.S. non-alcoholic steatohepatitis biomarkers competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 U.S. non-alcoholic steatohepatitis biomarkers market driver impact
• Fig. 14 U.S. non-alcoholic steatohepatitis biomarkers market restraint impact
• Fig. 15 U.S. non-alcoholic steatohepatitis biomarkers market: Type movement analysis
• Fig. 16 U.S. non-alcoholic steatohepatitis biomarkers market: Type outlook and key takeaways
• Fig. 17 Serum biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Hepatic fibrosis biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Apoptosis biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Oxidative stress biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Others estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 U.S. non-alcoholic steatohepatitis biomarkers market: End-use movement analysis
• Fig. 23 U.S. non-alcoholic steatohepatitis biomarkers market: End-use outlook and key takeaways
• Fig. 24 Pharma & CRO industry market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Diagnostic labs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Academic research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 U.S. non-alcoholic steatohepatitis biomarkers market: Regional movement analysis
• Fig. 29 U.S. non-alcoholic steatohepatitis biomarkers market: Regional outlook and key takeaways
• Fig. 30 West market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)